Paul Avillach, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Information Storage and Retrieval | 9 | 2019 | 821 | 1.540 |
Why?
|
Data Mining | 8 | 2018 | 550 | 1.120 |
Why?
|
Adverse Drug Reaction Reporting Systems | 9 | 2014 | 488 | 1.090 |
Why?
|
Chromosomes, Human, Pair 22 | 2 | 2024 | 347 | 1.020 |
Why?
|
MEDLINE | 2 | 2014 | 119 | 0.900 |
Why?
|
Chromosome Disorders | 2 | 2024 | 500 | 0.900 |
Why?
|
Databases, Factual | 19 | 2021 | 8000 | 0.880 |
Why?
|
Phenotype | 6 | 2024 | 16532 | 0.840 |
Why?
|
Medical Records Systems, Computerized | 8 | 2017 | 1192 | 0.800 |
Why?
|
Genetic Association Studies | 2 | 2024 | 2712 | 0.790 |
Why?
|
Chromosome Deletion | 2 | 2024 | 1387 | 0.780 |
Why?
|
Electronic Health Records | 17 | 2023 | 4737 | 0.690 |
Why?
|
International Classification of Diseases | 6 | 2020 | 882 | 0.660 |
Why?
|
Databases, Genetic | 4 | 2021 | 1740 | 0.580 |
Why?
|
Unified Medical Language System | 7 | 2020 | 89 | 0.550 |
Why?
|
Semantics | 3 | 2010 | 599 | 0.520 |
Why?
|
Serial Publications | 1 | 2014 | 11 | 0.490 |
Why?
|
PubMed | 1 | 2014 | 128 | 0.460 |
Why?
|
Nerve Tissue Proteins | 2 | 2024 | 4409 | 0.450 |
Why?
|
Drug Interactions | 2 | 2015 | 1424 | 0.450 |
Why?
|
Journal Impact Factor | 1 | 2014 | 156 | 0.440 |
Why?
|
Natural Language Processing | 4 | 2020 | 1128 | 0.420 |
Why?
|
Universities | 1 | 2017 | 980 | 0.410 |
Why?
|
Registries | 5 | 2024 | 8434 | 0.410 |
Why?
|
Sex Characteristics | 1 | 2022 | 2627 | 0.380 |
Why?
|
Medical Record Linkage | 1 | 2012 | 289 | 0.370 |
Why?
|
Methyltransferases | 1 | 2013 | 377 | 0.370 |
Why?
|
Vocabulary, Controlled | 3 | 2008 | 167 | 0.360 |
Why?
|
Purines | 1 | 2013 | 601 | 0.360 |
Why?
|
Medical Order Entry Systems | 1 | 2015 | 522 | 0.350 |
Why?
|
Pharmacogenetics | 1 | 2013 | 680 | 0.340 |
Why?
|
France | 7 | 2017 | 510 | 0.340 |
Why?
|
Europe | 12 | 2020 | 3429 | 0.330 |
Why?
|
Software | 5 | 2023 | 4421 | 0.310 |
Why?
|
Computational Biology | 2 | 2018 | 3505 | 0.310 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 3615 | 0.310 |
Why?
|
Information Dissemination | 4 | 2019 | 1132 | 0.310 |
Why?
|
Genome-Wide Association Study | 2 | 2020 | 12580 | 0.300 |
Why?
|
Medical Records | 5 | 2017 | 1406 | 0.300 |
Why?
|
Database Management Systems | 3 | 2017 | 258 | 0.280 |
Why?
|
Quantitative Trait Loci | 1 | 2013 | 2083 | 0.250 |
Why?
|
Genome, Human | 1 | 2018 | 4412 | 0.240 |
Why?
|
Mental Health | 2 | 2022 | 3195 | 0.240 |
Why?
|
Computer Security | 3 | 2014 | 260 | 0.220 |
Why?
|
Education, Medical, Graduate | 1 | 2015 | 2353 | 0.220 |
Why?
|
Acute Kidney Injury | 1 | 2015 | 1935 | 0.210 |
Why?
|
Medical Informatics | 3 | 2017 | 732 | 0.210 |
Why?
|
Pandemics | 4 | 2022 | 8609 | 0.190 |
Why?
|
Humans | 62 | 2024 | 759255 | 0.180 |
Why?
|
Dementia | 3 | 2020 | 2634 | 0.180 |
Why?
|
Internet | 5 | 2013 | 3073 | 0.180 |
Why?
|
Algorithms | 3 | 2021 | 13946 | 0.180 |
Why?
|
Pregnancy Complications | 3 | 2018 | 2940 | 0.170 |
Why?
|
Confidentiality | 4 | 2016 | 610 | 0.170 |
Why?
|
Infant | 7 | 2024 | 35941 | 0.170 |
Why?
|
Multilingualism | 1 | 2020 | 87 | 0.170 |
Why?
|
Suicide, Attempted | 2 | 2018 | 1387 | 0.160 |
Why?
|
Child, Preschool | 7 | 2024 | 41935 | 0.160 |
Why?
|
Computer Communication Networks | 1 | 2020 | 294 | 0.160 |
Why?
|
Suicidal Ideation | 2 | 2018 | 1429 | 0.150 |
Why?
|
Patient Discharge | 2 | 2008 | 3460 | 0.150 |
Why?
|
Product Surveillance, Postmarketing | 2 | 2013 | 450 | 0.150 |
Why?
|
Mental Disorders | 1 | 2017 | 6788 | 0.150 |
Why?
|
Terminology as Topic | 3 | 2010 | 1534 | 0.150 |
Why?
|
Sports | 2 | 2013 | 700 | 0.140 |
Why?
|
Adolescent | 14 | 2024 | 87560 | 0.140 |
Why?
|
Child | 13 | 2024 | 79623 | 0.140 |
Why?
|
Labor, Induced | 1 | 2018 | 151 | 0.140 |
Why?
|
Patient Identification Systems | 2 | 2007 | 75 | 0.140 |
Why?
|
Rare Diseases | 1 | 2021 | 619 | 0.130 |
Why?
|
Hospitalization | 6 | 2022 | 10734 | 0.130 |
Why?
|
Obstetric Labor Complications | 1 | 2018 | 236 | 0.130 |
Why?
|
Medical Subject Headings | 2 | 2012 | 16 | 0.130 |
Why?
|
Infant, Newborn | 5 | 2022 | 26109 | 0.130 |
Why?
|
Hospitals, University | 1 | 2017 | 568 | 0.120 |
Why?
|
Behavior | 1 | 2017 | 539 | 0.120 |
Why?
|
Female | 27 | 2024 | 390240 | 0.120 |
Why?
|
Hospital Information Systems | 1 | 2017 | 396 | 0.120 |
Why?
|
Anemia, Macrocytic | 1 | 2014 | 54 | 0.120 |
Why?
|
Retinol-Binding Proteins | 1 | 2014 | 68 | 0.110 |
Why?
|
Male | 22 | 2024 | 358719 | 0.110 |
Why?
|
Family | 1 | 2024 | 3189 | 0.110 |
Why?
|
Prevalence | 5 | 2022 | 15641 | 0.110 |
Why?
|
Triage | 1 | 2020 | 982 | 0.110 |
Why?
|
Quality of Health Care | 1 | 2008 | 4359 | 0.110 |
Why?
|
Selection Bias | 1 | 2014 | 358 | 0.110 |
Why?
|
Demography | 1 | 2017 | 1648 | 0.100 |
Why?
|
Odds Ratio | 3 | 2022 | 9711 | 0.100 |
Why?
|
Young Adult | 9 | 2024 | 58483 | 0.100 |
Why?
|
Limit of Detection | 1 | 2013 | 281 | 0.100 |
Why?
|
Reference Standards | 2 | 2013 | 1002 | 0.100 |
Why?
|
Liver Failure, Acute | 1 | 2014 | 180 | 0.100 |
Why?
|
Privacy | 1 | 2014 | 233 | 0.100 |
Why?
|
Data Collection | 1 | 2021 | 3317 | 0.100 |
Why?
|
Netherlands | 3 | 2020 | 2209 | 0.090 |
Why?
|
Access to Information | 3 | 2014 | 320 | 0.090 |
Why?
|
Nervous System Diseases | 1 | 2021 | 1645 | 0.090 |
Why?
|
False Positive Reactions | 1 | 2013 | 956 | 0.090 |
Why?
|
Automation | 1 | 2013 | 580 | 0.090 |
Why?
|
Antirheumatic Agents | 1 | 2020 | 1372 | 0.090 |
Why?
|
Adult | 12 | 2024 | 219390 | 0.080 |
Why?
|
International Cooperation | 2 | 2014 | 1436 | 0.080 |
Why?
|
Health Services Research | 1 | 2017 | 1809 | 0.080 |
Why?
|
Cesarean Section | 1 | 2018 | 1387 | 0.080 |
Why?
|
Genomics | 3 | 2020 | 5775 | 0.080 |
Why?
|
Out-of-Hospital Cardiac Arrest | 1 | 2013 | 346 | 0.080 |
Why?
|
Italy | 2 | 2020 | 840 | 0.070 |
Why?
|
Students | 1 | 2017 | 1718 | 0.070 |
Why?
|
Databases, Bibliographic | 1 | 2008 | 130 | 0.070 |
Why?
|
Knowledge Bases | 1 | 2008 | 98 | 0.070 |
Why?
|
Cost-Benefit Analysis | 1 | 2020 | 5500 | 0.070 |
Why?
|
Comorbidity | 1 | 2022 | 10547 | 0.070 |
Why?
|
Pregnancy Outcome | 1 | 2018 | 2901 | 0.070 |
Why?
|
Severity of Illness Index | 2 | 2021 | 15815 | 0.070 |
Why?
|
Information Systems | 1 | 2008 | 398 | 0.070 |
Why?
|
Benchmarking | 1 | 2012 | 1040 | 0.070 |
Why?
|
Prescription Drugs | 1 | 2013 | 630 | 0.060 |
Why?
|
Documentation | 1 | 2012 | 885 | 0.060 |
Why?
|
Retrospective Studies | 9 | 2023 | 80121 | 0.060 |
Why?
|
Middle Aged | 16 | 2023 | 219653 | 0.060 |
Why?
|
Myocardial Infarction | 2 | 2019 | 11888 | 0.060 |
Why?
|
Death, Sudden, Cardiac | 1 | 2013 | 1572 | 0.060 |
Why?
|
Incidence | 4 | 2019 | 21336 | 0.060 |
Why?
|
Sensitivity and Specificity | 2 | 2021 | 14652 | 0.060 |
Why?
|
Cohort Studies | 4 | 2023 | 41247 | 0.060 |
Why?
|
Hospital Administration | 1 | 2008 | 354 | 0.060 |
Why?
|
Arthritis, Rheumatoid | 1 | 2020 | 3762 | 0.060 |
Why?
|
Biomedical Research | 2 | 2019 | 3416 | 0.060 |
Why?
|
Risk Factors | 7 | 2020 | 74167 | 0.060 |
Why?
|
Feasibility Studies | 1 | 2014 | 5194 | 0.060 |
Why?
|
Liver | 1 | 2019 | 7514 | 0.060 |
Why?
|
Aged | 11 | 2023 | 168617 | 0.050 |
Why?
|
Psychotic Disorders | 1 | 2018 | 3170 | 0.050 |
Why?
|
Hypertension | 2 | 2020 | 8594 | 0.050 |
Why?
|
Smoking | 1 | 2019 | 9066 | 0.050 |
Why?
|
Reproducibility of Results | 3 | 2023 | 20031 | 0.050 |
Why?
|
Age Distribution | 2 | 2018 | 2892 | 0.050 |
Why?
|
Exercise | 1 | 2017 | 5773 | 0.050 |
Why?
|
Statistics as Topic | 1 | 2007 | 2364 | 0.050 |
Why?
|
Continuity of Patient Care | 1 | 2008 | 1060 | 0.050 |
Why?
|
Systems Integration | 2 | 2017 | 426 | 0.050 |
Why?
|
Emergency Service, Hospital | 1 | 2020 | 7788 | 0.050 |
Why?
|
Phenylcarbamates | 1 | 2020 | 37 | 0.050 |
Why?
|
Aged, 80 and over | 4 | 2021 | 58867 | 0.040 |
Why?
|
Galantamine | 1 | 2020 | 33 | 0.040 |
Why?
|
Indans | 1 | 2020 | 91 | 0.040 |
Why?
|
Pilot Projects | 1 | 2013 | 8540 | 0.040 |
Why?
|
Diet | 1 | 2017 | 8002 | 0.040 |
Why?
|
Venous Thromboembolism | 1 | 2012 | 1849 | 0.040 |
Why?
|
Pulmonary Embolism | 1 | 2012 | 2536 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 17750 | 0.040 |
Why?
|
Ecosystem | 1 | 2023 | 488 | 0.040 |
Why?
|
Alzheimer Disease | 1 | 2020 | 8540 | 0.040 |
Why?
|
Fetal Distress | 1 | 2018 | 39 | 0.040 |
Why?
|
Kidney | 1 | 2014 | 7066 | 0.040 |
Why?
|
Spain | 1 | 2019 | 486 | 0.040 |
Why?
|
Ethics Committees, Research | 1 | 2019 | 197 | 0.040 |
Why?
|
Peer Review, Research | 1 | 2021 | 341 | 0.040 |
Why?
|
Healthcare Disparities | 1 | 2013 | 3368 | 0.040 |
Why?
|
Fetal Macrosomia | 1 | 2018 | 131 | 0.040 |
Why?
|
Stroke | 1 | 2019 | 9935 | 0.040 |
Why?
|
Fetal Membranes, Premature Rupture | 1 | 2018 | 137 | 0.040 |
Why?
|
Abruptio Placentae | 1 | 2018 | 118 | 0.030 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2020 | 12268 | 0.030 |
Why?
|
Pregnancy | 4 | 2018 | 29658 | 0.030 |
Why?
|
Puerperal Disorders | 1 | 2018 | 300 | 0.030 |
Why?
|
Stillbirth | 1 | 2018 | 365 | 0.030 |
Why?
|
Adenocarcinoma | 1 | 2012 | 6311 | 0.030 |
Why?
|
Research Personnel | 1 | 2019 | 582 | 0.030 |
Why?
|
Postpartum Hemorrhage | 1 | 2018 | 265 | 0.030 |
Why?
|
Fetal Growth Retardation | 1 | 2018 | 578 | 0.030 |
Why?
|
Megestrol Acetate | 1 | 2013 | 18 | 0.030 |
Why?
|
Cisapride | 1 | 2013 | 22 | 0.030 |
Why?
|
Domperidone | 1 | 2013 | 24 | 0.030 |
Why?
|
Biological Specimen Banks | 1 | 2019 | 777 | 0.030 |
Why?
|
Metoclopramide | 1 | 2013 | 51 | 0.030 |
Why?
|
Betamethasone | 1 | 2013 | 44 | 0.030 |
Why?
|
Publishing | 1 | 2021 | 837 | 0.030 |
Why?
|
Defibrillators | 1 | 2013 | 40 | 0.030 |
Why?
|
Erythrocyte Indices | 1 | 2014 | 145 | 0.030 |
Why?
|
ROC Curve | 1 | 2021 | 3570 | 0.030 |
Why?
|
Methotrexate | 1 | 2020 | 1714 | 0.030 |
Why?
|
Blood Cell Count | 1 | 2014 | 398 | 0.030 |
Why?
|
Congenital Abnormalities | 1 | 2018 | 704 | 0.030 |
Why?
|
European Union | 1 | 2014 | 156 | 0.030 |
Why?
|
Fluconazole | 1 | 2013 | 155 | 0.030 |
Why?
|
Swimming | 1 | 2013 | 206 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2012 | 165 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2020 | 21988 | 0.030 |
Why?
|
Bicycling | 1 | 2013 | 176 | 0.030 |
Why?
|
Professional Practice | 1 | 2014 | 313 | 0.030 |
Why?
|
Azithromycin | 1 | 2013 | 201 | 0.030 |
Why?
|
Life Support Care | 1 | 2013 | 222 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 2019 | 12522 | 0.020 |
Why?
|
Piperidines | 1 | 2020 | 1649 | 0.020 |
Why?
|
Molecular Weight | 1 | 2014 | 2186 | 0.020 |
Why?
|
Prognosis | 3 | 2021 | 29561 | 0.020 |
Why?
|
Risk Assessment | 3 | 2019 | 24049 | 0.020 |
Why?
|
Language | 1 | 2020 | 1525 | 0.020 |
Why?
|
Logistic Models | 2 | 2018 | 13309 | 0.020 |
Why?
|
Reference Values | 1 | 2017 | 4918 | 0.020 |
Why?
|
Child Welfare | 1 | 2014 | 517 | 0.020 |
Why?
|
Informed Consent | 1 | 2016 | 1008 | 0.020 |
Why?
|
Running | 1 | 2013 | 483 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2021 | 25860 | 0.020 |
Why?
|
Disclosure | 1 | 2014 | 738 | 0.020 |
Why?
|
Age Factors | 2 | 2017 | 18394 | 0.020 |
Why?
|
Hospitals | 1 | 2021 | 3930 | 0.020 |
Why?
|
Catheterization, Central Venous | 1 | 2012 | 526 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39216 | 0.020 |
Why?
|
Fibrosis | 1 | 2014 | 2041 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2012 | 3468 | 0.020 |
Why?
|
Premature Birth | 1 | 2018 | 1765 | 0.020 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2013 | 1001 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2014 | 2168 | 0.020 |
Why?
|
Massachusetts | 1 | 2018 | 8788 | 0.020 |
Why?
|
Blood Pressure | 1 | 2020 | 8523 | 0.020 |
Why?
|
World Health Organization | 1 | 2011 | 1317 | 0.010 |
Why?
|
Lung | 1 | 2023 | 9982 | 0.010 |
Why?
|
Hospital Mortality | 1 | 2018 | 5414 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2018 | 7790 | 0.010 |
Why?
|
United States | 3 | 2018 | 72237 | 0.010 |
Why?
|
Residence Characteristics | 1 | 2013 | 2035 | 0.010 |
Why?
|
Time Factors | 2 | 2017 | 40109 | 0.010 |
Why?
|
Prospective Studies | 2 | 2020 | 54204 | 0.010 |
Why?
|
Acute Disease | 1 | 2013 | 7262 | 0.010 |
Why?
|
United States Food and Drug Administration | 1 | 2011 | 1676 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2012 | 6532 | 0.010 |
Why?
|
Disease Progression | 1 | 2018 | 13479 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 2010 | 2694 | 0.010 |
Why?
|
Obesity | 1 | 2023 | 12896 | 0.010 |
Why?
|
Recurrence | 1 | 2012 | 8469 | 0.010 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2014 | 2286 | 0.010 |
Why?
|
Survival Rate | 1 | 2013 | 12800 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12152 | 0.010 |
Why?
|
Computer Simulation | 1 | 2012 | 6195 | 0.010 |
Why?
|
Anticoagulants | 1 | 2012 | 4897 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15264 | 0.010 |
Why?
|
Models, Biological | 1 | 2012 | 9466 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2012 | 13621 | 0.010 |
Why?
|